Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Total Non-Current Liabilities: 2016-2025

Historic Total Non-Current Liabilities for Rocket Pharmaceuticals (RCKT) over the last 9 years, with Sep 2025 value amounting to $53.3 million.

  • Rocket Pharmaceuticals' Total Non-Current Liabilities fell 15.09% to $53.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.3 million, marking a year-over-year decrease of 15.09%. This contributed to the annual value of $63.3 million for FY2024, which is 10.60% down from last year.
  • As of Q3 2025, Rocket Pharmaceuticals' Total Non-Current Liabilities stood at $53.3 million, which was down 18.88% from $65.7 million recorded in Q2 2025.
  • Rocket Pharmaceuticals' Total Non-Current Liabilities' 5-year high stood at $96.4 million during Q1 2021, with a 5-year trough of $42.2 million in Q4 2021.
  • Moreover, its 3-year median value for Total Non-Current Liabilities was $57.8 million (2025), whereas its average is $59.7 million.
  • Within the past 5 years, the most significant YoY rise in Rocket Pharmaceuticals' Total Non-Current Liabilities was 41.00% (2022), while the steepest drop was 55.93% (2022).
  • Over the past 5 years, Rocket Pharmaceuticals' Total Non-Current Liabilities (Quarterly) stood at $42.2 million in 2021, then skyrocketed by 41.00% to $59.5 million in 2022, then climbed by 18.99% to $70.8 million in 2023, then declined by 10.60% to $63.3 million in 2024, then decreased by 15.09% to $53.3 million in 2025.
  • Its Total Non-Current Liabilities was $53.3 million in Q3 2025, compared to $65.7 million in Q2 2025 and $57.8 million in Q1 2025.